Cure­Vac jumps in­to coro­n­avirus vac­cine race; EMA backs raft of drugs, in­clud­ing No­vo Nordisk, Es­pe­ri­on com­pounds

→ You can add Cure­Vac to the list of new play­ers to jump in­to the lat­est ef­fort to con­tain a pan­dem­ic. The mR­NA com­pa­ny has joined the glob­al crew al­ready on board with the pub­lic-pri­vate Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions, which is adding up to $8.3 mil­lion to rapid­ly de­vel­op, man­u­fac­ture and test a new vac­cine for the coro­n­avirus 2019-nCoV. The Ger­man biotech is the lat­est biotech to see if new tech can ad­dress a scary virus that ev­i­dent­ly kills some 3% to 4% of the peo­ple who are in­fect­ed by it. Oth­ers, in­clud­ing Mod­er­na and Vir, are al­so us­ing new tech de­vel­oped over the last decade to see if they can come up with a quick way to stop the spread of the Wuhan virus, which is rat­tling pop­u­la­tions around the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER